Europe - Frankfurt Stock Exchange - FRA:IDP - US09062X1037 - Common Stock
We assign a fundamental rating of 6 out of 10 to IDP. IDP was compared to 86 industry peers in the Biotechnology industry. IDP has outstanding health and profitabily ratings, belonging to the best of the industry. This is a solid base for any company. IDP is valued quite cheap, but it does not seem to be growing. These ratings would make IDP suitable for value investing!
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 5.51% | ||
| ROE | 8.84% | ||
| ROIC | 9.7% |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 28.5% | ||
| PM (TTM) | 15.98% | ||
| GM | 75.24% |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.35 | ||
| Debt/FCF | 2.78 | ||
| Altman-Z | 3.28 |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.72 | ||
| Quick Ratio | 2.04 |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 10.39 | ||
| Fwd PE | 11.25 |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 11.28 | ||
| EV/EBITDA | 7.64 |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
ChartMill assigns a fundamental rating of 6 / 10 to IDP.DE.
ChartMill assigns a valuation rating of 7 / 10 to BIOGEN INC (IDP.DE). This can be considered as Undervalued.
BIOGEN INC (IDP.DE) has a profitability rating of 7 / 10.
The financial health rating of BIOGEN INC (IDP.DE) is 7 / 10.
The Earnings per Share (EPS) of BIOGEN INC (IDP.DE) is expected to decline by -7.54% in the next year.